HEAR IT FIRST WITH OUR DAILY NEWSLETTER



We don't spam. Learn more about our Privacy Policy

Bod’s medicinal cannabis wafer is taking shape – with manufacture of stock for its trial to begin in the weeks to come.

It makes administering cannabis as easy as dissolving a wafer on a patient’s tongue – the cannabis extract freeze dried for quick and efficient absorption.

Manufacture of trial stock by its partner iX Biopharma is set to commence in the coming weeks, with Phase 1 Clinical trials to start shortly after.

“A positive trial outcome will leave the company with a unique, patent protected, standardised and reproducible cannabis product which may be sold or licensed to major pharmaceutical companies” it told the market today.

And Bod is already actively exploring potential licence and export opportunities for the wafer form.

Bod (BDA) shares over the past three months.
Bod (BDA) shares over the past three months.

Shares in the company (ASX:BDA) were trading flat at 42c on Friday morning.

Today’s news follows its receipt of full ethics approval for the trial earlier this month.

According to the company, approval was granted in an unprecedented timeframe due to the quality of the extract and the parties involved.

Alongside trials, Bod will sell its imported cannabis oils to patients through the Special Access Scheme – with imports expected in the coming weeks.

Chief Jo Patterson said the sale of oils would be in consultation with health professionals to understand the benefits.

“The company looks to commence educational and support initiatives to all relevant specialists and pharmacies as soon as possible and to progress agreements, where applicable, for centralised distribution points through approved pharmacies.”